Get the Stockscreener App
10.49
2.87%
-0.31
After Hours:
10.49
Regenxbio Inc stock is traded at $10.49, with a volume of 656.33K.
It is down -2.87% in the last 24 hours and down -14.16% over the past month.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
See More
Previous Close:
$10.80
Open:
$10.81
24h Volume:
656.33K
Relative Volume:
1.29
Market Cap:
$509.55M
Revenue:
$89.04M
Net Income/Loss:
$-241.08M
P/E Ratio:
-1.6598
EPS:
-6.32
Net Cash Flow:
$-194.72M
1W Performance:
-10.11%
1M Performance:
-14.16%
6M Performance:
-50.21%
1Y Performance:
-36.27%
1-Day Range:
$10.14
$10.95
1-Week Range:
$10.14
$11.89
52-Week Range:
$10.14
$28.80
Regenxbio Inc Stock (RGNX) Company Profile
Name
Regenxbio Inc
Sector
Industry
Phone
240-552-8181
Address
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-01-23 | Initiated | Stifel | Buy |
| Jun-02-23 | Initiated | Robert W. Baird | Outperform |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Dec-15-21 | Initiated | Wedbush | Neutral |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Jan-06-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Aug-20-19 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Jun-18-19 | Reiterated | Chardan Capital Markets | Buy |
| Jun-14-19 | Resumed | Raymond James | Outperform |
| Jun-05-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-25-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-05-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-17-18 | Reiterated | Chardan Capital Markets | Buy |
| Nov-08-18 | Reiterated | BofA/Merrill | Neutral |
| Aug-08-18 | Reiterated | Chardan Capital Markets | Buy |
| Jul-23-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-10-18 | Reiterated | Chardan Capital Markets | Buy |
| May-09-18 | Reiterated | Barclays | Overweight |
| Apr-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-13-18 | Initiated | Mizuho | Neutral |
| Nov-09-17 | Resumed | Morgan Stanley | Overweight |
View All
Regenxbio Inc Stock (RGNX) Latest News
REGENXBIO's SWOT analysis: gene therapy stock poised for growth amid challenges - Investing.com
REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
A company insider recently sold 10,000 shares of Regenxbio Inc [RGNX]. Should You Sale? - Knox Daily
Regenxbio Inc (RGNX) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
RGNX’s Financial Health: Exploring Regenxbio Inc’s Debt-to-Equity Ratio of 1.79 - The InvestChronicle
The Potential Rise in the Price of Regenxbio Inc (RGNX) following insiders activity - Knox Daily
Do investors need to be concerned about Regenxbio Inc (RGNX)? - US Post News
REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines Conference - StockTitan
Insider’s View: Deciphering Regenxbio Inc (RGNX)’s Financial Health Through Ratios - The Dwinnex
REGENXBIO Inc. (NASDAQ:RGNX) Shares Bought by Integral Health Asset Management LLC - MarketBeat
There is no way Regenxbio Inc (RGNX) can keep these numbers up - SETE News
REGENXBIO (NASDAQ:RGNX) Upgraded by StockNews.com to Hold - MarketBeat
MRP Capital Investments LLC Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - Defense World
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Meiji Yasuda Asset Management Co Ltd. Purchases 119 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - Defense World
Acadian Asset Management LLC Buys Shares of 42,292 REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat
Moors & Cabot Inc. Has $858,000 Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - Defense World
A closer look at Regenxbio Inc (RGNX) is warranted - US Post News
Stock Surge: Regenxbio Inc (RGNX) Closes at 12.53, Marking a -3.24 Increase/Decrease - The Dwinnex
Wealth Alliance Sells 13 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - Defense World
GoodRx Holdings Inc (GDRX) requires closer examination - US Post News
REGENXBIO (NASDAQ:RGNX) Shares Down 3.1% - MarketBeat
3 Genomics Stocks Transforming Healthcare - Entrepreneur
Argent Trust Co Has $2.49 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - Defense World
Federated Hermes Inc. Has $3.98 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Acadian Asset Management LLC Invests $494,000 in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
Regulus Therapeutics (NASDAQ:RGLS) Stock Rating Upgraded by StockNews.com - Defense World
Guardian Pharmacy Services, Inc. (GRDN) Plans to Raise $102 Million in September 26th IPO - Defense World
Repligen financial statements require restatement due to revenue recognition error - Seeking Alpha
REGENXBIO (NASDAQ:RGNX) Shares Down 3.1% - Defense World
Ratios Reveal: Breaking Down Regency Centers Corporation (REG)’s Financial Health - The Dwinnex
Potential Price Increase for Regenxbio Inc (RGNX) After Recent Insider Activity - Knox Daily
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Envestnet Asset Management Inc. - Defense World
Regency Centers Co. (NASDAQ:REG) Position Cut by DekaBank Deutsche Girozentrale - Defense World
Regeneron Pharmaceuticals’ (REGN) “Outperform” Rating Reaffirmed at Royal Bank of Canada - Defense World
Cantor Fitzgerald Reiterates Neutral Rating for Regeneron Pharmaceuticals (NASDAQ:REGN) - Defense World
REGENXBIO names Mitchell Chan as new CFO amid growth phase - Investing.com
Regency Centers (NASDAQ:REG) Stock Rating Lowered by Evercore ISI - Defense World
RegenXBio Appoints New EVP and CFO Amidst Key Developments - TipRanks
Geron (NASDAQ:GERN) Trading 7.1% Higher - MarketBeat
Guardian Pharmacy seeks to raise up to $108 mil in US IPO - AlphaStreet
Garmin Rises 34% Year to Date: How Should You Play the Stock? - Yahoo Finance
Regeneron Pharmaceuticals' (REGN) Outperform Rating Reiterated at Royal Bank of Canada - MarketBeat
REGENXBIO names Mitchell Chan as new CFO amid growth phase By Investing.com - Investing.com Australia
BMO holds stock target, outperform rating on Regeneron shares - Investing.com India
Regenxbio Appoints Chief Financial Officer - Contract Pharma
Thoroughbred Financial Services LLC Acquires New Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - Defense World
REGENXBIO Appoints Mitchell Chan as Chief Financial Officer - citybiz
REGENXBIO names Mitchell Chan as new CFO amid growth phase By Investing.com - Investing.com UK
REGENXBIO Appoints Mitchell Chan as Chief Financial Officer - Longview News-Journal
Ashton Thomas Private Wealth LLC Buys Shares of 37 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - Defense World
Regenxbio Inc Stock (RGNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):